Renal Anemia Clinical Trial
Official title:
The Association Between the Distributions MCH and RBC, and Mortality in a Cohort of Chronic Hemodialysis Patients: a 3-year Retrospective Observational Study
Patients were classified into two groups based on the values of MCH and RBC, patients with MCH ≥30 pg but <35 pg and RBC ≤350×104/μL; and MCH <30 pg and RBC >350×104/μL. Associations between all-cause mortality and the distributions of MCH and RBC were assessed by Kaplan-Meier curves and Cox proportional hazards regression model.
The Hb levels generally provides the value of RBC and iron status because mean corpuscular hemoglobin MCH is derived from the Hb divided by RBC. MCH depends on the size and concentration of erythrocytes. Thus, the value of RBC and MCH depend on dose of ESA and iron, respectively. Guidelines for Renal Anemia in Chronic Kidney Disease of 2015 Japanese Society for Dialysis Therapy recommend administration hemoglobin (Hb) levels ≥10 g/dL but <12 g/dL in dialysis patients.Patients whose Hb levels is maintained at 10 to 12 g/dL, Hb levels is widely distributed when divided into RBC and MCH. Therefore, the investigators examined the prognosis of life in the distribution of MCH and RBC. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Active, not recruiting |
NCT03388385 -
Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
|
Phase 4 | |
Completed |
NCT05035641 -
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
|
Phase 2 | |
Completed |
NCT02299661 -
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
|
Phase 1 | |
Active, not recruiting |
NCT05265325 -
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
|
Phase 2 | |
Completed |
NCT05864261 -
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
|
Phase 4 | |
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02708914 -
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
|
Phase 3 | |
Completed |
NCT02041208 -
Variability of Hemoglobin Levels After Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT04775615 -
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00298441 -
Efficacy of Intravenous Iron Administration in Hemodialysis Patients
|
Phase 4 | |
Active, not recruiting |
NCT04408820 -
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
|
||
Completed |
NCT01543477 -
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
|
||
Completed |
NCT05951192 -
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
|
Phase 4 | |
Completed |
NCT04454879 -
Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients
|
Phase 4 | |
Recruiting |
NCT04360902 -
Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT03480178 -
Renal Anemia Refractory to Erythropoietin
|
||
Completed |
NCT01306409 -
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
|
Phase 4 | |
Completed |
NCT00322413 -
Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial
|
Phase 3 | |
Recruiting |
NCT05970172 -
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
|
Phase 3 |